In sum, our findings not only uncover a novel role of EZH2 in regulating MDSC development, but also suggest that to achieve better anticancer outcomes, pharmacological inhibition of EZH2 in cancer therapy should be used in combination with MDSC depletion. Here, EZH2 is linked to cancer.